Last reviewed · How we verify
Zilretta
At a glance
| Generic name | Zilretta |
|---|---|
| Also known as | triamcinolone acetonide, Extended release triamcinolone acetonide, FX006, Triamcinolone acetonide extended-release, triamcinolone acetonide, extended release injectable suspension |
| Sponsor | Sorrento Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Local Methotrexate Injections for the Treatment of Nail Psoriasis (PHASE4)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zilretta CI brief — competitive landscape report
- Zilretta updates RSS · CI watch RSS
- Sorrento Therapeutics, Inc. portfolio CI